Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects

NCT00244751 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

265

Enrollment

INDUSTRY

Sponsor class

Conditions

Cirrhosis, Liver

Interventions

DRUG: GI262570 0.5 mg
DRUG: GI262570 1.0 mg
DRUG: Placebo

Sponsor

GlaxoSmithKline